Tranexamic acid and blood loss during and after cesarean section: a meta-analysis

• Published in: Journal of perinatology Vol. 35; no. 10; pp. 818 - 825
• Main Authors: Wang, H-Y, Hong, S-K, Duan, Y, Yin, H-M
• Format: Journal Article
• Language: English
• Published: New York Nature Publishing Group US 01.10.2015; Nature Publishing Group
• Subjects: 692/308/409; 692/700/459/1748; Antifibrinolytic agents; Antifibrinolytic Agents - therapeutic use; Blood Loss, Surgical - prevention & control; Blood Transfusion; Blood Volume; Care and treatment; Cesarean section; Cesarean Section - adverse effects; Complications and side effects; Confidence intervals; Drug therapy; Female; Hematocrit; Hemoglobin; Hemorrhage; Humans; Intraoperative Complications - prevention & control; Intravenous administration; Medicine; Medicine & Public Health; Meta-analysis; original-article; Patient outcomes; Pediatric Surgery; Pediatrics; Postoperative Complications - prevention & control; Postpartum; Pregnancy; Publication Bias; Randomized Controlled Trials as Topic; Risk factors; Statistical analysis; Tranexamic acid; Tranexamic Acid - therapeutic use; Transfusion; China
• ISSN: 0743-8346; 1476-5543
• DOI: 10.1038/jp.2015.93

Objective: A meta-analysis of randomized controlled trials (RCTs) was conducted to evaluate whether tranexamic acid (TXA) could significantly reduce blood loss during and after cesarean section (CS) when compared with no TXA. Study design: MEDLINE (PubMed), EMBASE, Cochrane Central Register of Controlled Trials and Web of Science were searched to identify RCTs that compared intravenous TXA with no TXA before CS for blood loss. The related data were extracted by two independent authors. The fixed or random-effect methods were used to combine data. Result: Eleven RCTs were included in this analysis with a total of 1276 women in TXA group and 1255 in no TXA (control) group. Total blood loss during and after CS was significantly less in TXA group than in control group (mean difference (MD) −141.61 ml, 95% confidence interval (CI) −207.09 to −76.14, P <0.01). There was a significant reduction in intraoperative and postpartum blood loss in TXA group as compared with control group (MD −143.36 ml, 95% CI −220.38 to −66.35, P <0.01; and MD −38.20 ml, 95% CI −59.27 to −17.12, P <0.01, respectively). Declines in hemoglobin and hematocrit values after CS were both significantly less in TXA group than in control group. The difference of postpartum hemorrhage rate was statistically significant between groups (risk ratio (RR) 0.57, 95% CI 0.37 to 0.89, P =0.01). The need for blood transfusion was significantly less in TXA group than control group (RR 0.23, 95% CI 0.10 to 0.57, P <0.01). Conclusion: Our results demonstrate that TXA offers an advantage over no TXA in reducing blood loss during and after CS.